OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director

Chief Development Officer of OKYO Pharma increases shareholding signaling confidence ahead of pivotal Phase 3 trial

OKYO Pharma Limited announced that its Chief Development Officer and Director, Gary S. Jacob, PhD, has purchased an additional 3,500 ordinary shares on NASDAQ, increasing his total holdings to over 112,000 shares. This insider buying comes as the company prepares to initiate a global Phase 3 clinical trial of urcosimod for treating neuropathic corneal pain later this year.

OKYO

Summarize with

ChatGPT Perplexity Claude Grok Gemini

Key Points

Insider buying by Chief Development Officer Gary S. Jacob indicates strong confidence in the company’s prospects.
OKYO Pharma is on track to start a pivotal Phase 3 clinical trial for urcosimod targeting neuropathic corneal pain within the second half of 2026.
The company operates in the biopharmaceutical sector, specifically focusing on novel therapies for eye diseases, impacting investors in biotech and healthcare markets.

LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that Gary S. Jacob, PhD, Chief Development Officer and Director of OKYO Pharma has increased his holdings with the purchase of 3,500 of the Company’s ordinary shares on NASDAQ at $1.40 per share, bringing his total holding to 112,420 ordinary shares.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.

For further information, please visit www.okyopharma.com.

For further inquiries:

OKYO Pharma Ltd
Paul Spencer
Business Development and Investor Relations
+44 (0) 207 495 2379
Email: [email protected]

Risks

Clinical trials carry inherent risks; the success of the Phase 3 trial for urcosimod is uncertain and crucial for the company’s future revenue and growth.
Market acceptance and regulatory approvals of the investigational therapy are not guaranteed, which could delay product launch or commercialization.
Stock price volatility may increase due to dependence on clinical trial outcomes and limited product diversification, affecting investor sentiment in biotech equities.

Menu

OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director

Key Points

Risks

More from Press Releases